On February 23, 2024 Oncopeptides, a biotech company focused on difficult-to-treat cancers, reported that the U.S. Food and Drug Administration (FDA) has made a decision regarding the withdrawal of Pepaxto, which Oncopeptides had appealed (Press release, Oncopeptides, FEB 23, 2024, View Source [SID1234646780]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In their decision, the FDA concludes that they have determined that the grounds for withdrawing the approval have been met. The full decision is, or will momentarily be, available in the public docket created by the FDA through the following link. Oncopeptides will now thoroughly assess the decision.

Oncopeptides’ focus remains on commercialization in Europe where the company has a full marketing authorization.